Summary
GlobalData, the industry analysis specialist's new report, "Brain Tumour-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global brain tumour market. The report identifies the key trends shaping and driving the global brain tumour market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global brain tumour sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global brain tumour market revenues data from 2000 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global brain tumour market.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with brain tumour.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global brain tumour market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global brain tumour market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global brain tumour market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Brain Tumor: Market Characterization 5
2.1 Brain Tumor Market Size 5
2.2 Brain Tumor Market Forecasts and Compound Annual Growth Rate 5
2.3 Drivers and Barriers for the Brain Tumor Market 6
2.3.1 Drivers for the Brain Tumor Market 6
2.3.2 Barriers for the Brain Tumor Market 6
2.4 Opportunity and Unmet Need 6
2.5 Key Takeaway 7
3 Brain Tumor Market: Competitive Assessment 9
3.1 Overview 9
3.2 Strategic Competitor Assessment 9
3.3 Product Profile for the Major Marketed Products in the Brain Tumor Market 10
3.3.1 Temodar 10
3.3.2 Avastin 11
3.3.3 Gliadel 11
3.4 Major Marketed Products Comparison in the Brain Tumor Market 13
3.5 Key Takeaway 13
4 Global Brain Tumor Market: Pipeline Assessment 14
4.1 Overview 14
4.2 Strategic Pipeline Assessment 14
4.2.1 Technology Trends Analytic Framework 14
4.3 Brain tumor Therapeutics-Promising Drugs under Clinical Development 16
4.4 Molecule Profile for Promising Drugs under Clinical Development 17
4.4.1 Cilengitide 17
4.4.2 Trabedersen 17
4.4.3 Neuradiab 18
4.4.4 XL184 (BMS-907351) 19
4.5 Brain Tumor Therapeutics Market-Clinical Pipeline by Mechanism of Action 20
4.6 Brain Tumor Pipeline-Pipeline by Clinical Phases of Development 21
4.6.1 Brain Tumor Therapeutics-Regulatory and Phase III Clinical Pipeline 22
4.6.2 Brain Tumor Therapeutics-Phase II Clinical Pipeline 23
4.6.3 Brain Tumor Therapeutics-Phase I Clinical Pipeline 27
4.6.4 Brain Tumor Therapeutics-Preclinical Pipeline 29
4.7 Key Takeaway 30
5 Global Brain Tumor Market: Implications for Future Market Competition 31
6 Global Brain Tumor Market: Future Players in the Brain Tumor Market 32
6.1 Introduction 32
6.2 AstraZeneca 32
6.2.1 Company Overview 32
6.2.2 Business Description 33
6.3 GlaxoSmithKline plc. 35
6.3.1 Company Overview 35
6.3.2 Business Description 36
6.4 Bristol-Myers Squibb 38
6.4.1 Company Overview 38
6.4.2 Business Description 39
6.5 Pfizer Inc. 40
6.5.1 Company Overview 40
6.5.2 Business Description 41
6.6 Eli Lilly and Company 45
6.6.1 Company Overview 45
6.6.2 Business Description 45
6.6.3 Oncology Portfolio 46
6.7 F. Hoffmann-La Roche Ltd (Roche) 46
6.7.1 Company Overview 46
6.7.2 Business Description 47
6.8 Novartis AG 49
6.8.1 Company Overview 49
6.8.2 Business Description 49
6.9 Merck & Co., Inc 52
6.9.1 Company Overview 52
6.9.2 Business Description 53
7 Global Brain Tumor Market: Appendix 54
7.1 Definitions 54
7.2 Acronyms 54
7.3 Research Methodology 54
7.3.1 Coverage 55
7.3.2 Secondary Research 55
7.3.3 Forecasting 56
7.3.4 Primary Research 58
7.3.5 Expert Panels 59
7.4 Contact Us 59
7.5 Disclaimer 59
7.6 Sources 60

List of Tables
1.1 List of Tables
Table 1: Global Brain Tumor Therapeutics Market Forecast, Revenue Forecasts ($m), 2009-2016 5
Table 2: Brain tumor Therapeutics-Most Promising Drugs Under Clinical Development, 2010 16
Table 3: Brain Therapeutics-Phase III Clinical Pipeline, 2010 22
Table 4: Brain Tumor Therapeutics-Phase II Clinical Pipeline, 2010 23
Table 5: Brain Tumor Therapeutics-Phase I Clinical Pipeline, 2010 27
Table 6: Brain Tumor Therapeutics-Preclinical Pipeline, 2010 29
Table 7: Bristol-Myers Squibb Company-Oncology Pipeline Products, 2010 40
Table 8: Bristol-Myers Squibb Company-Brain Tumor Pipeline Products, 2009 40
Table 9: Eli Lilly and Company-Brain Tumor Pipeline Products, 2010 46
Table 10: F. Hoffmann-La Roche Ltd.-Brain Tumor Pipeline Products 49
Table 11: Novartis AG-Brain Tumor  Pipeline Products, 2010 52

List of Figures
1.2 List of Figures
Figure 1: Global Brain Tumor Therapeutics Market Forecast, 2009-2016 5
Figure 2: Brain Tumor Therapeutics Market-Opportunity and Unmet Need, 2010 7
Figure 3: Brain Tumor Therapeutics Market-Strategic Competitor Assessment, 2010 9
Figure 4: Technology Trends Analytic Framework of the Brain Tumor Pipeline, 2010 14
Figure 5: Technology Trends Analytic Framework of the Brain Tumor Pipeline-Description, 2010 15
Figure 6: Brain Tumor Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 21
Figure 7: Brain Tumor Pipeline by Phase of Clinical Development, 2010 21
Figure 8: Implications for Future Market Competition in the Brain Tumor Market, 2010 31
Figure 9: Brain Tumor Therapeutics Market-Clinical Pipeline by Company , 2010 32
Figure 10: GlobalData Market Forecasting Model 58